ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation

NCT04082897 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

CLL Transformation

Interventions

DRUG: Obinutuzumab 25 MG/ML [Gazyva]
DRUG: Atezolizumab 60 MG/ML [Tecentriq]
DRUG: Venetoclax Oral Tablet

Sponsor

Niguarda Hospital